AYTU BIOPHARMA, INC Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
AYTU BIOPHARMA, INC (AYTU) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $22.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2023-11-14
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2023-09-30 was $22.00K, a 15.38% decline year-over-year.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2023-06-30 was $23.00K, a 11.54% decline year-over-year.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2022-09-30 was $26.00K, a 4.00% increase year-over-year.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2022-06-30 was $26.00K, a 96.00% decline year-over-year.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2023 was $96.00K, a 99.40% decline from fiscal 2022.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2022 was $16.10M, a 1563.33% increase from fiscal 2021.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2021 was $968.00K, a 95.02% decline from fiscal 2020.
- AYTU BIOPHARMA, INC repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2020 was $19.44M.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month as first filed | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-09-30 | $22.00K 10-Q · filed 2023-11-14 | $45.00K derived: sum of 2 quarters · filed 2023-11-14 | ||||
| 2023-06-30 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $96.00K 10-K · filed 2023-10-12 | ||||
| 2023-03-31 | $73.00K 10-Q · filed 2023-05-11 | |||||
| 2022-09-30 | $26.00K 10-Q · filed 2023-11-14 | $52.00K derived: sum of 2 quarters · filed 2023-11-14 | -$73.50M derived: sum of 3 quarters · filed 2023-11-14 | $16.10M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | -$73.53M derived: sum of 2 quarters · filed 2023-10-12 | $16.08M derived: sum of 3 quarters · filed 2023-10-12 | $16.10M 10-K · filed 2023-10-12 | ||
| 2022-03-31 | -$73.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $16.05M derived: sum of 2 quarters · filed 2023-05-11 | $16.07M 10-Q · filed 2023-05-11 | $16.73M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $89.61M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-02-14 | $89.63M 10-Q · filed 2022-02-14 | $90.28M derived: sum of 3 quarters · filed 2023-02-21 | $90.33M derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2021-09-30 | $25.00K 10-Q/A · filed 2023-02-21 | $45.65M 10-Q · filed 2021-11-15 | $675.00K derived: sum of 2 quarters · filed 2023-02-21 | $720.00K derived: sum of 3 quarters · filed 2023-02-21 | $857.00K derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $695.00K derived: sum of 2 quarters · filed 2022-09-27 | $832.00K derived: sum of 3 quarters · filed 2022-09-27 | $968.00K 10-K · filed 2022-09-27 | $54.95M 10-K · filed 2021-09-28 | |
| 2021-03-31 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $182.00K derived: sum of 2 quarters · filed 2022-05-16 | $318.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $273.00K 10-Q · filed 2022-02-14 | ||||
| 2020-09-30 | $136.00K 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $19.44M 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |